Koh Mark Jean-Ann, Giam Yoke Chin, Liew Hui Min, Foong Alice Yee-Wah, Chong Jin Ho, Wong Sharon Mun Yee, Tang Mark Boon Yang, Ho Madeline Sheun Ling, Tan Lucinda Siyun, Mason James M, Cork Michael J
KK Women's and Children's Hospital, Bukit Timah, Singapore, Singapore.
National Skin Centre, Mandalay Road, Singapore, Singapore.
Dermatol Ther (Heidelb). 2017 Sep;7(3):383-393. doi: 10.1007/s13555-017-0186-1. Epub 2017 Jun 14.
Patient eczema severity time (PEST) is a new atopic dermatitis (AD) scoring system based on patients' own perception of their disease. Conventional scales such as SCORing of atopic dermatitis (SCORAD) reflect the clinician's observations during the clinic visit. Instead, the PEST score captures eczema severity, relapse and recovery as experienced by the patient or caregiver on a daily basis, promoting patient engagement, compliance with treatment and improved outcomes. This study aims to determine the correlation between carer-assessed PEST and clinician-assessed SCORAD in paediatric AD patients after 12 weeks of treatment using a ceramide-dominant therapeutic moisturizer.
Prospective, open-label, observational, multi-centre study in which children with AD aged 6 months to 6 years were treated with a ceramide dominant therapeutic moisturizer twice daily for 12 weeks; 58 children with mild-to-moderate AD were included. Correlation between the 7-day averaged PEST and SCORAD scores for assessment of AD severity was measured within a general linear model. PEST and SCORAD were compared in week 4 and week 12.
At week 12, a moderate correlation was found between the SCORAD and PEST scores (r = 0.51). The mean change in SCORAD and PEST scores from baseline to week 12 was -11.46 [95% confidence interval (CI) -14.99 to -7.92, p < 0.0001] and -1.33 (95% CI -0.71 to -0.10, p < 0.0001) respectively. PEST demonstrated greater responsiveness to change (33.3% of scale) compared to SCORAD (13.8% of scale).
The PEST score correlates well with the SCORAD score and may have improved sensitivity when detecting changes in the severity of AD. The ceramide-dominant therapeutic moisturizer used was safe and effective in the management of AD in young children.
Hyphens Pharma Pte Ltd.
clinicaltrials.gov identifier, NCT02073591.
患者湿疹严重程度时间(PEST)是一种基于患者自身对疾病感知的新型特应性皮炎(AD)评分系统。传统的量表,如特应性皮炎评分(SCORAD),反映的是临床医生在门诊就诊时的观察结果。相反,PEST评分记录了患者或护理人员日常所经历的湿疹严重程度、复发和恢复情况,有助于提高患者的参与度、治疗依从性并改善治疗效果。本研究旨在确定在使用以神经酰胺为主的治疗性保湿剂治疗12周后,儿科AD患者中由护理人员评估的PEST与临床医生评估的SCORAD之间的相关性。
一项前瞻性、开放标签、观察性、多中心研究,对6个月至6岁的AD患儿每日两次使用以神经酰胺为主的治疗性保湿剂治疗12周;纳入58例轻至中度AD患儿。在一般线性模型中测量用于评估AD严重程度的7天平均PEST和SCORAD评分之间的相关性。在第4周和第12周对PEST和SCORAD进行比较。
在第12周时,发现SCORAD和PEST评分之间存在中度相关性(r = 0.51)。从基线到第12周,SCORAD和PEST评分的平均变化分别为-11.46 [95%置信区间(CI)-14.99至-7.92,p < 0.0001]和-1.33(95% CI -0.71至-0.10,p < 0.